Xalkori is an anti-cancer drug owned by Pf Prism Cv. The drug contains the active ingredient crizotinib and was granted market authorization on 26 August, 2011. Xalkori currently holds five patents, none of which have yet expired.
The possibility for Xalkori generics appears to be after the 6th of November, 2029, which marks the expiry date of the last-held patent. This would allow for the cheaper, generic versions of the drug to be made available to the public.
Xalkori is mainly used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. It can also be used to reverse or inhibit the progress of unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive in adult and pediatric patients 1 year of age and older. Additionally, the drug is used for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Xalkori holds a total of five patents, with the last one expected to expire on November 6, 2029. With this, Xalkori generic drugs could potentially enter the market soon after this date. Below are the details of the patent: